Patient-Specific Orthotopic Glioblastoma Xenograft Models Recapitulate the Histopathology and Biology of Human Glioblastomas In Situ

Cell Reports

Volumn 3, Issue 1, 2013, Pages 260-273

  Joo, Kyeung Min ^a,b   Kim, Jinkuk ^b,c   Jin, Juyoun ^a   Kim, Misuk ^a   Seol, Ho Jun ^a   Muradov, Johongir ^a   Yang, Heekyoung ^a   Choi, Yoon La ^a   Park, Woong Yang ^a   Kong, Doo Sik ^a   Lee, Jung Il ^a   Ko, Young Hyeh ^a,b   Woo, Hyun Goo ^d   Lee, Jeongwu ^e   Kim, Sunghoon ^f   Nam, Do Hyun ^a,b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Samsung Medical Center   (South Korea)

^c SAMSUNG Electronics   (South Korea)

^d Ajou University School of Medicine   (South Korea)

^e LERNER RESEARCH INSTITUTE   (United States)

^f Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DRUG TARGETING; GENE IDENTIFICATION; GENE LIBRARY; GENOMICS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR MODEL; TUMOR XENOGRAFT;

ADULT; AGED; ANIMALS; BRAIN NEOPLASMS; CELL SHAPE; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENOME, HUMAN; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; SPHEROIDS, CELLULAR; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84873110988     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2012.12.013     Document Type: Article

References (44)

1. Adamson C., Kanu O.O., Mehta A.I., Di C., Lin N., Mattox A.K., Bigner D.D. Glioblastoma multiforme: a review of where we have been and where we are going. Expert Opin. Investig. Drugs 2009, 18:1061-1083.
2. Antunes L., Angioi-Duprez K.S., Bracard S.R., Klein-Monhoven N.A., Le Faou A.E., Duprez A.M., Plénat F.M. Analysis of tissue chimerism in nude mouse brain and abdominal xenograft models of human glioblastoma multiforme: what does it tell us about the models and about glioblastoma biology and therapy?. J. Histochem. Cytochem. 2000, 48:847-858.
3. Bonavia R., Inda M.M., Cavenee W.K., Furnari F.B. Heterogeneity maintenance in glioblastoma: a social network. Cancer Res. 2011, 71:4055-4060.
4. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
5. Charles N.A., Holland E.C., Gilbertson R., Glass R., Kettenmann H. The brain tumor microenvironment. Glia 2011, 59:1169-1180.
6. Chi A.S., Wen P.Y. Inhibiting kinases in malignant gliomas. Expert Opin. Ther. Targets 2007, 11:473-496.
7. Clark N.R., Ma'ayan A. Introduction to statistical methods for analyzing large data sets: gene-set enrichment analysis. Sci. Signal. 2011, 4:tr4.
8. de Groot J.F., Fuller G., Kumar A.J., Piao Y., Eterovic K., Ji Y., Conrad C.A. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro. Oncol. 2010, 12:233-242.
9. DeRose Y.S., Wang G., Lin Y.C., Bernard P.S., Buys S.S., Ebbert M.T., Factor R., Matsen C., Milash B.A., Nelson E., et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 2011, 17:1514-1520.
10. Fu X., Guadagni F., Hoffman R.M. A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc. Natl. Acad. Sci. USA 1992, 89:5645-5649.
11. Furnari F.B., Fenton T., Bachoo R.M., Mukasa A., Stommel J.M., Stegh A., Hahn W.C., Ligon K.L., Louis D.N., Brennan C., et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007, 21:2683-2710.
12. Giannini C., Sarkaria J.N., Saito A., Uhm J.H., Galanis E., Carlson B.L., Schroeder M.A., James C.D. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro. Oncol. 2005, 7:164-176.
13. Groves M.D., Puduvalli V.K., Hess K.R., Jaeckle K.A., Peterson P., Yung W.K., Levin V.A. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J. Clin. Oncol. 2002, 20:1383-1388.
14. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
15. Horten B.C., Basler G.A., Shapiro W.R. Xenograft of human malignant glial tumors into brains of nude mice. A histopathological study. J. Neuropathol. Exp. Neurol. 1981, 40:493-511.
16. Hoshida Y. Nearest template prediction: a single-sample-based flexible class prediction with confidence assessment. PLoS ONE 2010, 5:e15543.
17. Ito M., Hiramatsu H., Kobayashi K., Suzue K., Kawahata M., Hioki K., Ueyama Y., Koyanagi Y., Sugamura K., Tsuji K., et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood 2002, 100:3175-3182.
18. Joo K.M., Kim S.Y., Jin X., Song S.Y., Kong D.S., Lee J.I., Jeon J.W., Kim M.H., Kang B.G., Jung Y., et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab. Invest. 2008, 88:808-815.
19. Karam J.A., Zhang X.Y., Tamboli P., Margulis V., Wang H., Abel E.J., Culp S.H., Wood C.G. Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma. Eur. Urol. 2011, 59:619-628.
20. Kong D.S., Song S.Y., Kim D.H., Joo K.M., Yoo J.S., Koh J.S., Dong S.M., Suh Y.L., Lee J.I., Park K., et al. Prognostic significance of c-Met expression in glioblastomas. Cancer 2009, 115:140-148.
21. Lai A., Tran A., Nghiemphu P.L., Pope W.B., Solis O.E., Selch M., Filka E., Yong W.H., Mischel P.S., Liau L.M., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 2011, 29:142-148.
22. Langley R.R., Fidler I.J. The seed and soil hypothesis revisited-the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer 2011, 128:2527-2535.
23. Lathia J.D., Heddleston J.M., Venere M., Rich J.N. Deadly teamwork: neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 2011, 8:482-485.
24. Lee J., Kotliarova S., Kotliarov Y., Li A., Su Q., Donin N.M., Pastorino S., Purow B.W., Christopher N., Zhang W., et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006, 9:391-403.
25. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., Scheithauer B.W., Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
26. Lutz K., Radbruch A., Wiestler B., Bäumer P., Wick W., Bendszus M. Neuroradiological response criteria for high-grade gliomas. Clin Neuroradiol 2011, 21:199-205.
27. Madhavan S., Zenklusen J.C., Kotliarov Y., Sahni H., Fine H.A., Buetow K. REMBRANDT: helping personalized medicine become a reality through integrative translational research. Mol. Cancer Res. 2009, 7:157-167.
28. Marangoni E., Vincent-Salomon A., Auger N., Degeorges A., Assayag F., de Cremoux P., de Plater L., Guyader C., De Pinieux G., Judde J.G., et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin. Cancer Res. 2007, 13:3989-3998.
29. Martens T., Laabs Y., Günther H.S., Kemming D., Zhu Z., Witte L., Hagel C., Westphal M., Lamszus K. Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2. Clin. Cancer Res. 2008, 14:5447-5458.
30. Nicholas M.K., Lukas R.V., Chmura S., Yamini B., Lesniak M., Pytel P. Molecular heterogeneity in glioblastoma: therapeutic opportunities and challenges. Semin. Oncol. 2011, 38:243-253.
31. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
32. Pollard S.M., Yoshikawa K., Clarke I.D., Danovi D., Stricker S., Russell R., Bayani J., Head R., Lee M., Bernstein M., et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4:568-580.
33. Rubio-Viqueira B., Jimeno A., Cusatis G., Zhang X., Iacobuzio-Donahue C., Karikari C., Shi C., Danenberg K., Danenberg P.V., Kuramochi H., et al. An in vivo platform for translational drug development in pancreatic cancer. Clin. Cancer Res. 2006, 12:4652-4661.
34. Sausville E.A., Burger A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 2006, 66:3351-3354. discussion 3354.
35. Son M.J., Woolard K., Nam D.H., Lee J., Fine H.A. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009, 4:440-452.
36. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., Belanger K., Brandes A.A., Marosi C., Bogdahn U., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials GroupNational Cancer Institute of Canada Clinical Trials Group.
37. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
38. Taillandier L., Antunes L., Angioi-Duprez K.S. Models for neuro-oncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice. J. Neurosci. Methods 2003, 125:147-157.
39. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110. Cancer Genome Atlas Research Network.
40. Wang J., Miletic H., Sakariassen P.Ø., Huszthy P.C., Jacobsen H., Brekkå N., Li X., Zhao P., Mørk S., Chekenya M., et al. A reproducible brain tumour model established from human glioblastoma biopsies. BMC Cancer 2009, 9:465.
41. Xie Q., Thompson R., Hardy K., DeCamp L., Berghuis B., Sigler R., Knudsen B., Cottingham S., Zhao P., Dykema K., et al. A highly invasive human glioblastoma pre-clinical model for testing therapeutics. J. Transl. Med. 2008, 6:77.
42. Yang S.H., Kim Y.H., Kim J.W., Park C.K., Park S.H., Jung H.W. Methylation status of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene promoter in World Health Organization grade III gliomas. J Korean Neurosurg. Soc. 2009, 46:385-388.
43. Yi D., Hua T.X., Lin H.Y. EGFR gene overexpression retained in an invasive xenograft model by solid orthotopic transplantation of human glioblastoma multiforme into nude mice. Cancer Invest. 2011, 29:229-239.
44. Zhuo Y., Wu Y., Guo A., Chen S., Su J. [Establishment and its biological characteristics of patient-derived lung cancer xenograft models]. Zhongguo. Fei. Ai. Za. Zhi. 2010, 13:568-574.